September 28, 2026

FDA Expands Merck’s Welireg Label for a New Kidney Cancer Indication – Yahoo Finance

September 28, 2026

Merck expands Welireg’s use to broader set of kidney cancer patients – Endpoints News

September 28, 2026

FDA Approves Belzutifan + Lenvatinib for Clear Cell Kidney Cancer – Memorial Sloan Kettering Cancer Center

September 25, 2026

Merck, Eisai’s Welireg-Lenvima combo lands FDA nod to jump the kidney cancer queue – Fierce Pharma

September 25, 2026

FDA Approves Belzutifan-Lenvatinib Combo for Advanced Kidney Cancer – The American Journal of Managed Care